Under the Paperwork Reduction Act of 1995, no persons are required to resp

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number				
Filing Date				
First Named Inventor Flori		an EISELE		
Art Unit				
Examiner Name Not		fet Assigned		
Attorney Docket Number		052460-19US M/ERB-157PCUS		

	U.S.PATENTS						Remove				
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Patentee or Applicant of cited Document				nt Passage	
	1	5545195		1996-0	8-13	LENNOX et al.					
	2	6475213	B1	2002-1	1-05	5 WHAYNE ot al.					
	3	5496311		1996-0	3-05	ABELE et al.					
	4	6090105		2000-0	7-18	ZEPEDA et al	L				
If you wis	n to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Patentee or Applicant of cited Document		Releva		ines where es or Relevar	
	1	20030130572	A1	2003-0	7-10	PHAN et al.					
If you wis	n to a	d additional U.S. Publi:	shed Ap	plication	citation	n information p	olease click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	vhere Rele	r Relevant	

	Application Number			
NEODMATION DIGGI COURT	Filing Date			
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Floria	an EISELE	
Not for submission under 37 CFR 1.99)	Art Unit			
	Examiner Name Not Y		Yet Assigned	
	Attorney Docket Numb	er	052460-19US M/ERB-157PCUS	

	1	199 41 105	DE	C2	2003-02-27	ERBE Elektromedizin GmbH		-
If you wisi	h to a	dd additional Forei	gn Patent Docum	ent citation	information p	lease click the Add butto	Add	
			NON-PA	TENT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner linitials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.							Тs
	1							
If you wish	h to a	dd additional non-p	atent literature d	ocument ci	tation informat	ion please click the Add	button Add	
				EXAMINE	R SIGNATUR	Έ		
Examiner	Signa	ture				Date Considered		
*EXAMIN	ER: Ir	itial if reference co	nsidered, whether	er or not cit	ation is in cont	ormance with MPEP 609	Draw line through a	

See Knd Code of USPTO Patent Documents at insex_ISETO_GOL/ or MPEP 901.04. 2 finite of this that issued the document, by the low-letter code (WIPO Standard 513.). For Laplanese patent counters, the architaction of the year of the register or precedure to see and represent the sent number for patent document. If knd of coursent by the appropriate symbols as enducated on the document under WIPO Standard 51.16 if possible. Sppicant is to place a check mark here if English language translation is altached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number | Filing Date | Filing Date | Filing Date | Filing Manage Inventor | Filing Date | Filing Manage Inventor | Filing Manage Inven

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement, See 37 CPR 1.97(e/t1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

.7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/WILLIAM W. SCHWARZE/	Date (YYYY-MM-DD)	2006-08-21
Name/Drint	William W. Schwarze	Registration Number	25 018

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenian's (Office, U.S. Operatment of Commence, P. 0. Bast 1450, Alexandria, V.32.11-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.211-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.